305 related articles for article (PubMed ID: 31862616)
1. Current trends in the pharmacological management of Chagas disease.
Ribeiro V; Dias N; Paiva T; Hagström-Bex L; Nitz N; Pratesi R; Hecht M
Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():7-17. PubMed ID: 31862616
[TBL] [Abstract][Full Text] [Related]
2. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
[TBL] [Abstract][Full Text] [Related]
3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
4. New Approaches for the Treatment of Chagas Disease.
Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
[TBL] [Abstract][Full Text] [Related]
5. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
[TBL] [Abstract][Full Text] [Related]
6. In Silico Drug Repositioning for Chagas Disease.
Bellera CL; Alberca LN; Sbaraglini ML; Talevi A
Curr Med Chem; 2020; 27(5):662-675. PubMed ID: 31622200
[TBL] [Abstract][Full Text] [Related]
7. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
Sulleiro E; Muñoz-Calderon A; Schijman AG
Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
[TBL] [Abstract][Full Text] [Related]
8. Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi.
Sangenito LS; Menna-Barreto RFS; d'Avila-Levy CM; Branquinha MH; Santos ALS
Curr Med Chem; 2019; 26(36):6590-6613. PubMed ID: 31187704
[TBL] [Abstract][Full Text] [Related]
9. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
10. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
11. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological in vitro and in vivo Evaluation of 2-(5-Nitroindazol-1-yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease.
Martín-Escolano R; Aguilera-Venegas B; Marín C; Martín-Montes Á; Martín-Escolano J; Medina-Carmona E; Arán VJ; Sánchez-Moreno M
ChemMedChem; 2018 Oct; 13(19):2104-2118. PubMed ID: 30098232
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo experimental models for drug screening and development for Chagas disease.
Romanha AJ; Castro SL; Soeiro Mde N; Lannes-Vieira J; Ribeiro I; Talvani A; Bourdin B; Blum B; Olivieri B; Zani C; Spadafora C; Chiari E; Chatelain E; Chaves G; Calzada JE; Bustamante JM; Freitas-Junior LH; Romero LI; Bahia MT; Lotrowska M; Soares M; Andrade SG; Armstrong T; Degrave W; Andrade Zde A
Mem Inst Oswaldo Cruz; 2010 Mar; 105(2):233-8. PubMed ID: 20428688
[TBL] [Abstract][Full Text] [Related]
14. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
15. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
16. Perspectives for a new drug candidate for Chagas disease therapy.
Soeiro MNC
Mem Inst Oswaldo Cruz; 2022; 117():e220004. PubMed ID: 35293439
[TBL] [Abstract][Full Text] [Related]
17. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
Urbina JA
J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
[TBL] [Abstract][Full Text] [Related]
18. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
19. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
20. Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi.
Simões-Silva MR; De Araújo JS; Peres RB; Da Silva PB; Batista MM; De Azevedo LD; Bastos MM; Bahia MT; Boechat N; Soeiro MNC
Parasitology; 2019 Jul; 146(8):1006-1012. PubMed ID: 30859917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
